Horizon Therapeutics (HZNP) – Press Releases
-
Rule 17(e) Announcement - Horizon Therapeutics plc
-
Rule 17(d) Announcement – Horizon Therapeutics plc
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Horizon Therapeutics plc Announces New UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be presented at ECTRIMS 2023
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
New Analysis Highlights Importance of Adhering to Uninterrupted Full Course of Treatment with TEPEZZA® (teprotumumab-trbw) to Support Thyroid Eye Disease (TED) Patient Outcomes
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Horizon Therapeutics plc Named to U.S. News & World Report’s 2024 List of Best Companies to Work For in the Health Care Industry
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Horizon Therapeutics plc Ranks Number One on the Fortune Best Workplaces in Biopharma 2023 List
-
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
-
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
-
Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement
-
Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition
-
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by Rare Disease Patient Advocacy Groups
-
Horizon Therapeutics plc - Rule 2.12 Announcement
-
Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Horizon Therapeutics plc Announces 2023 #RAREis Global Advocate Grant Recipients
-
Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Daxdilimab for the Treatment of Systemic Lupus Erythematosus (SLE) Did Not Meet Primary Endpoint
-
Horizon Therapeutics plc to Release Second-Quarter 2023 Financial Results on Aug. 8, 2023
-
Long-Term Data From the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection With Methotrexate Published in ACR Open Rheumatology
-
New Analysis of MRI Findings Shows UPLIZNA® (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People With Neuromyelitis Optica Spectrum Disorder (NMOSD)
-
TEPEZZA® (teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease (TED)
-
Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED)
-
NIRI Chicago Elects 2023-2024 Officers and Directors
-
Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of D
-
New Data from TEPEZZA® (teprotumumab-trbw) Clinical Trials and Real-World Analyses Shed Light on Link Between Thyroid Autoimmunity and Hearing Risks
-
Horizon Therapeutics plc (“Horizon”) Rule 2.12 Announcement
-
UPLIZNA® (inebilizumab-cdon) Pivotal Trial Publication Integrating MRI and Biomarker Evaluation Shows Accuracy and Uniformity of Attack Diagnoses for Neuromyelitis Optica Spectrum Disorder (NMOSD)
-
Horizon Therapeutics plc announces premium partnership with KPMG Women’s Irish Open
-
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocri
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cd
-
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
-
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
-
Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
-
Horizon Therapeutics plc Responds to U.S. Federal Trade Commission (FTC) Action to Block Acquisition by Amgen
-
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
-
Horizon Therapeutics plc Ranks First in Overall Corporate Reputation by U.S. Patient Advocacy Groups
-
Horizon Therapeutics plc (“Horizon”) - Rule 2.12 Announcement
-
Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
-
Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Back to HZNP Stock Lookup
